Media Center

In the media

Ability Pharma seeks 2.5 million to expand clinical trials

Expansión

09/10/2017

Ability Pharma receives the OK from France for testing a new drug

Diari Sabadell

09/10/2017

ABILITY PHARMA ACHIEVES THE DISTINCTION OF ORPHAN DRUG IN THE EU

Expansión

19/09/2017

REWARD TO MINORYX AND ABILITY AUDACITY

Expansión

15/12/2016

Ability Pharma strengthens in the US

El Periódico

14/12/2016

AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812

Diari de Sabadell

06/12/2016

The phase 2 of the antitumoral drug starts

La Vanguardia

23/11/2016

Start of a clinical trial with a new drug for lung and endometiral cancer

La Vanguardia online

22/11/2016

ABTL0812, from AbilityPharmaceuticals, is designed Orphan

Diaro Médico

08/04/2015

European support to the oncology investigation

La Vanguardia

08/04/2015

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma

Siege to cancer from Bellaterra

L'Econòmic - El Punt Avui

19/02/2013

The biomedical company Ability Pharmaceuticals obtains financing for a pioneering treatment for pancreatic and lung cancer in humans

Ability Pharma, 1.2 million to enter clinical phase.

La Vanguardia

11/02/2013

Ability Pharma raises 1 million euros for a new drug.

Expansión

07/02/2013

Financing rounds of Catalan start-ups in 2012

Expansión

04/02/2013

After closing its financing round, Ability Pharmaceuticals – formerly AB-Therapeutics - split from the parent company AB-Biotics and changed its name

AB-Therapeutics raises one million euros and becomes Ability Pharmaceuticals.

Expansión

22/09/2012

AB-Therapeutics closes a financing round.

El Punt-Avui

21/09/2012

AB-Therapeutics gets one million funding for new drug.

El Economista

21/09/2012

AB-Therapeutics closes a financing round of one million euros.

Cinco Días

21/09/2012

AB-Therapeutics obtains resources to move forward in its R&D in oncology.

Diario Médico

21/09/2012

AB-Therapeutics closes a financing round of one million Euros and changes its name to Ability Pharmaceuticals.

Diari de Sabadell

19/09/2012

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits